Sodium Nitroprusside In 0.9% Sodium Chloride Injection
NDC Package 70436-207-80

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Sodium Nitroprusside In 0.9% Sodium Chloride injection is diseases with compensatory hypertension (e.g., coarctation of the aorta, arteriovenous shunting).Inadequate cerebral circulation or in moribund patients (A.S.A. This formulation utilizes a injection delivery system. Marketed by Slate Run Pharmaceuticals, Llc, this product is identified by NDC 70436-207 and is authorized under FDA application ANDA215846.

Identification & Billing

NDC Package Code
70436-207-80
Package Description
1 VIAL, SINGLE-DOSE in 1 CARTON / 100 mL in 1 VIAL, SINGLE-DOSE
Product Code
11-Digit Billing Format
70436020780
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Sodium Nitroprusside In 0.9% Sodium Chloride
Non-Proprietary Name
Sodium Nitroprusside In 0.9% Sodium Chloride
Substance Name
Sodium Nitroprusside
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Usage Information
Diseases with compensatory hypertension (e.g., coarctation of the aorta, arteriovenous shunting).Inadequate cerebral circulation or in moribund patients (A.S.A. Class 5E) coming to emergency surgery.Patients with congenital (Leber’s) optic atrophy or with tobacco amblyopia.Acute heart failure associated with reduced peripheral vascular resistance.Concomitant use with sildenafil, tadalafil, vardenifil, or riociguat.

Regulatory & Marketing

Labeler Name
Slate Run Pharmaceuticals, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA215846
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-31-2022
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70436-207-80 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 100 ml in 1 vial, single-dose of Sodium Nitroprusside In 0.9% Sodium Chloride, a human prescription drug labeled by Slate Run Pharmaceuticals, Llc. This injection is formulated for intravenous use and contains sodium nitroprusside as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Slate Run Pharmaceuticals, Llc on December 31, 2022. The current certification is valid through December 31, 2026.

How is this Slate Run Pharmaceuticals, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70436020780. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70436-207-80
11-Digit CMS (5-4-2)
70436-0207-80

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.